Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.35 |
| ▸ | CHRNG | P07510 | 2/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.35 |
| ▸ | CHRND | Q07001 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22566699 | 0.88 | GLP1R (0.50) | GLP1RMEN1KMT2ANMT2NMT1 | |
| SCHEMBL20017564 | 0.83 | GLP1R (0.46) | GLP1RMEN1KMT2ANMT2NMT1 | |
| SCHEMBL20375472 | 0.82 | GLP1R (0.46) | GLP1RMEN1KMT2ANMT2NMT1 | |
| SCHEMBL18715475 | 0.82 | GLP1R (0.48) | GLP1RMEN1KMT2AGLO1CHRNA1 | |
| SCHEMBL13616087 | 0.82 | MEN1 (0.53) | GLP1RMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL20375605 | 0.81 | GLP1R (0.47) | GLP1RMEN1KMT2ANMT2NMT1 | |
| SCHEMBL20814382 | 0.81 | GLP1R (0.47) | GLP1RMEN1KMT2ACHRNA1CHRNG | |
| SCHEMBL26026996 | 0.80 | GLP1R (0.46) | GLP1RNMT2NMT1 | |
| SCHEMBL23714584 | 0.80 | GLP1R (0.46) | GLP1RMEN1KMT2AGLO1CHRNA1 | |
| SCHEMBL21287433 | 0.80 | GLP1R (0.46) | GLP1RMEN1KMT2ACHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-24 | — | — | US | disclosed |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) | 2021-12-30 | — | — | US | disclosed |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210100829-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2021-04-08 | — | — | US | disclosed |
| US-10780108-B2 | RNAi agents for Hepatitis B virus infection | Arrowhead Pharmaceuticals, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200263179-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF LPA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-08-20 | — | — | US | disclosed |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190292547-A1 | RNAi Agents for Hepatitis B Virus Infection | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-09-26 | — | — | US | disclosed |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | Arrowhead Pharmaceuticals, Inc. (US) | 2019-08-22 | — | — | US | disclosed |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056454-A1 | RNAi Agents for Inhibiting Expression of 17beta-HSD Type 13 (HSD17B13), Compositions Thereof, and Methods of Use | HSD17B13, HSD17B3, HSD17B10 | GLP1R 3037/4885MEN1 4798/4885KMT2A 3559/4885 |
| US-11590156-B2 | RNAi agents for hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885MEN1 3729/4885KMT2A 2337/4885 |
| US-10450565-B2 | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885MEN1 1361/4885KMT2A 3675/4885 |
| US-20180195069-A1 | Alpha-1 AntiTrypsin (AAT) RNAi Agents, Compositions Including AAT RNAi Agents, And Methods of Use | SERPINA2, SERPINC1, SERPINA3 | GLP1R 4004/4885MEN1 1361/4885KMT2A 3675/4885 |
| US-20210100829-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885MEN1 3729/4885KMT2A 2337/4885 |
| US-20210395745-A1 | RNAI AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, NR1H4 | GLP1R 3941/4885MEN1 3908/4885KMT2A 2074/4885 |
| US-10780108-B2 | RNAi agents for Hepatitis B virus infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885MEN1 3729/4885KMT2A 2337/4885 |
| US-20210403908-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS D VIRUS INFECTION | HAVCR2, EIF2AK2, HDGF | GLP1R 4794/4885MEN1 4687/4885KMT2A 3071/4885 |
| US-20190292547-A1 | RNAi Agents for Hepatitis B Virus Infection | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885MEN1 3729/4885KMT2A 2337/4885 |
| US-20190255091-A1 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | HAVCR2, ASGR1, HDGF | GLP1R 4156/4885MEN1 3729/4885KMT2A 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.